Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.

ABSTRACT:

Purpose of review

The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and safety of sequential immunotherapy with targeted therapy in patients with BRAF-mutated melanoma. It discusses criteria for the use of available options in clinical practice.

Recent findings

Targeted therapy provides rapid disease control in a relatively high proportion of patients, although the development of secondary resistance limits the duration of responses; in contrast, immunotherapy may induce slow but more durable responses in a subset of patients. Therefore, the identification of a combination strategy for the use of the

SUBMITTER: Trojaniello C 

PROVIDER: S-EPMC10164000 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature